Third-quarter 2017 biopharma financing reached $12.5 billion, just a 6% decrease from the previous quarter's $13.4 billion. (See Exhibit 1.) The most money was raised in the follow-on public offering category, which accounted for nearly half (49%) of the Q3 dollar volume. The average deal value increased to $124 million (versus $85 million in Q2), attributed to 20 of the 50 financings completed having a value of $100 million or more. The largest was Incyte Corp.'s $650 million September FOPO; part of the proceeds will fund R&D activities. [See Deal] In addition to Incyte's marketed oncology therapies Jakafi (ruxolitinib) and Iclusig (ponatinib; to which Incyte has exclusive European right per a 2016 deal with Ariad Pharmaceuticals Inc.[See Deal]), it has many more candidates in development across various therapeutic areas, including cancer, dermatology and immunology, with multiple partnered programs.
Biopharma Quarterly Dealmaking Statistics, Q3 2017
A look at financing, M&A and alliance activity July–September 2017
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
More from Deal-Making
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.
More from In Vivo
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.